| 1 |
34617381 | Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. | 2022 Feb |
1 |
| 2 |
35115614 | The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes. | 2022 Feb 3 |
1 |
| 3 |
33786273 | Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM). | 2021 Apr |
1 |
| 4 |
34285473 | Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. | 2021 |
2 |
| 5 |
34334532 | Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study. | 2021 Dec 28 |
4 |
| 6 |
31776304 | SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. | 2020 Jan 28 |
9 |
| 7 |
32100949 | Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome. | 2020 Sep |
2 |
| 8 |
32115517 | Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial. | 2020 |
1 |
| 9 |
32134370 | Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus. | 2020 |
1 |
| 10 |
32166619 | Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus. | 2020 Apr |
2 |
| 11 |
30536746 | Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. | 2019 Jul |
1 |
| 12 |
30800562 | Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study. | 2019 Jan |
1 |
| 13 |
30828082 | In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor. | 2019 |
6 |
| 14 |
30937121 | Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy. | 2019 Apr |
3 |
| 15 |
31026084 | Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus. | 2019 Aug |
1 |
| 16 |
31197753 | Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM. | 2019 Aug |
2 |
| 17 |
31237132 | A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor. | 2019 Dec |
1 |
| 18 |
31606880 | Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. | 2019 Dec |
2 |
| 19 |
31768494 | Mineral and Electrolyte Disorders With SGLT2i Therapy. | 2019 Nov |
1 |
| 20 |
32743434 | Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma. | 2019 Sep |
2 |
| 21 |
28846182 | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. | 2018 Feb |
1 |
| 22 |
29110406 | Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. | 2018 Jul |
2 |
| 23 |
29322485 | Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study. | 2018 Feb |
2 |
| 24 |
29479047 | Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. | 2018 Mar 19 |
1 |
| 25 |
29709913 | Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice. | 2018 |
2 |
| 26 |
29806620 | Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). | 2018 Aug 27 |
1 |
| 27 |
30234161 | Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. | 2018 |
1 |
| 28 |
27242192 | First case of drug eruption due to ipragliflozin: Case report and review of the literature. | 2017 Aug |
1 |
| 29 |
27841020 | Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. | 2017 Jan |
1 |
| 30 |
28090231 | Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study. | 2017 Feb |
2 |
| 31 |
28490565 | Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study). | 2017 May 9 |
1 |
| 32 |
28674356 | Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor. | 2017 |
3 |
| 33 |
28924123 | The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin. | 2017 Oct 15 |
4 |
| 34 |
26549210 | SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies. | 2016 |
1 |
| 35 |
26891133 | Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor. | 2016 Oct |
1 |
| 36 |
26914659 | Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. | 2016 Apr |
1 |
| 37 |
27081422 | Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. | 2016 May |
2 |
| 38 |
27619983 | Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. | 2016 Sep 13 |
1 |
| 39 |
27628105 | Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. | 2016 Dec |
1 |
| 40 |
27803440 | Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor. | 2016 |
1 |
| 41 |
25311502 | Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice. | 2015 Jan |
2 |
| 42 |
25328035 | Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. | 2015 |
3 |
| 43 |
25685284 | Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. | 2015 Feb 15 |
3 |
| 44 |
25805666 | Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. | 2015 Jul |
1 |
| 45 |
24668021 | Ipragliflozin: first global approval. | 2014 Apr |
3 |
| 46 |
25149596 | Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. | 2014 Oct |
2 |
| 47 |
25316572 | Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. | 2014 Nov |
2 |
| 48 |
25352807 | Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model. | 2014 |
1 |
| 49 |
23163880 | Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. | 2013 May |
1 |
| 50 |
23359360 | Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. | 2013 May |
1 |